Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other brokerages have also issued reports on EPRX. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $11.67.

Eupraxia Pharmaceuticals Trading Down 2.0%

Shares of EPRX opened at $6.27 on Friday. The firm has a fifty day moving average price of $5.99 and a 200-day moving average price of $5.45. The firm has a market capitalization of $225.47 million, a P/E ratio of -7.21 and a beta of 1.38. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $7.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in EPRX. Quadrature Capital Ltd purchased a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at $61,000. TCI Wealth Advisors Inc. bought a new stake in Eupraxia Pharmaceuticals during the third quarter valued at about $65,000. Integrated Wealth Concepts LLC purchased a new position in Eupraxia Pharmaceuticals in the third quarter valued at about $71,000. Bank of America Corp DE grew its stake in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.